Latest Partnerships News

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Askari Metals is gearing up for a pivotal shareholder meeting to approve its Ethiopian gold and copper acquisition, while restructuring debt and expanding European investor outreach.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Miramar Resources has partnered with Sumitomo Metal Mining Oceania in a multi-million-dollar joint venture to explore for large-scale nickel-copper-platinum group element deposits at the Bangemall Projects in Western Australia.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Cedar Woods Properties Limited delivered a robust FY25 with a 19% increase in net profit, underpinned by a diversified project portfolio and favourable market conditions. The company signals continued growth with a 10% NPAT guidance for FY26, supported by strong presales and strategic partnerships.

Cedar Woods Properties has reported a robust 19% rise in net profit for FY25, surpassing guidance with strong presales and strategic partnerships setting the stage for continued growth.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

The Australian Wealth Advisors Group Ltd (AWAG) reported a 13% revenue increase and a $1.2 million profit before tax in FY2025, driven by strategic Equity Partnership Scheme investments and a strong funds under management base.

The Australian Wealth Advisors Group Ltd (AWAG) reported a $1.18 million net profit before tax in its first full year as an ASX-listed company, reversing a prior loss and growing revenue by 13%. The company expanded its funds under management and equity investments, positioning itself for further industry consolidation.